Last reviewed · How we verify

Low-dose tamoxifen — Competitive Intelligence Brief

Low-dose tamoxifen (Low-dose tamoxifen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM). Area: Oncology.

phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Low-dose tamoxifen (Low-dose tamoxifen) — National Taiwan University Hospital. Low-dose tamoxifen acts as a selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while potentially having immunomodulatory effects at reduced doses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Low-dose tamoxifen TARGET Low-dose tamoxifen National Taiwan University Hospital phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα)
Bazedoxifene/Conjugated Estrogen Bazedoxifene/Conjugated Estrogen University of North Carolina, Chapel Hill marketed Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Clomiphene citrate and Estradiol Clomiphene citrate and Estradiol Maher elesawi kamel elesawi marketed Selective estrogen receptor modulator (SERM) combined with estrogen replacement Estrogen receptor alpha and beta
teriparatide and raloxifene teriparatide and raloxifene Medical University of Vienna marketed Combination therapy: PTH analog and selective estrogen receptor modulator (SERM) PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)
Low-dose Clomiphene Low-dose Clomiphene Weill Medical College of Cornell University marketed Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β)
fenofibrate and tibolone fenofibrate and tibolone Keogh Institute for Medical Research marketed Fibrate + Selective Estrogen Receptor Modulator (SERM) PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
High Dose Clomiphencitrat High Dose Clomiphencitrat University Hospital, Basel, Switzerland marketed Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) class)

  1. University Hospital, Basel, Switzerland · 2 drugs in this class
  2. AstraZeneca · 2 drugs in this class
  3. Estetra · 1 drug in this class
  4. Fundació Privada Eugin · 1 drug in this class
  5. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
  6. National Taiwan University Hospital · 1 drug in this class
  7. Oregon Health and Science University · 1 drug in this class
  8. Samsung Medical Center · 1 drug in this class
  9. Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class
  10. Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-dose tamoxifen — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-tamoxifen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: